GlassScriptPhysician profile
Orlan Kenneth Macdonald
NPI 1760543755
$1,041.44
in general payments reported to CMS, 2019-2025
25 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.13 · 2022: $26.74 · 2023: $31.86 · 2024: $349 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.11 | 2024-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $137.71 | 2024-2025 | |
| Intuitive Surgical, INC. | $65.00 | 2025 | |
| Progenics Pharmaceuticals, INC. | $59.66 | 2025 | |
| Merck Sharp & Dohme LLC | $52.29 | 2025 | Reblozyl, Lynparza, Keytruda |
| Exelixis INC. | $52.15 | 2024-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $48.35 | 2025 | |
| Elekta, INC. | $47.13 | 2021 | |
| Astellas Pharma US INC | $40.23 | 2024-2025 | Vyloy |
| Myriad Genetic Laboratories, INC. | $34.47 | 2022-2023 | Myrisk |
| Agios Pharmaceuticals, INC. | $34.45 | 2025 | Pyrukynd |
| Tersera Therapeutics LLC | $29.81 | 2025 | Xermelo |
| Sumitomo Pharma America, INC. | $27.98 | 2025 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $24.80 | 2025 | Ninlaro |
| Lilly USA, LLC | $24.49 | 2024 | Verzenio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $19.68 | 2024 | Elzonris |
| Beigene USA, INC. | $19.58 | 2025 | Brukinsa |
| Pfizer INC. | $19.42 | 2025 | |
| Incyte Corporation | $17.86 | 2024 | Monjuvi, Pemazyre |
| Aveo Pharmaceuticals, INC. | $17.69 | 2025 | |
| Bioprotect Medical, INC. | $17.16 | 2025 | Bioprotect Balloon Implant System |
| Alnylam Pharmaceuticals INC. | $15.49 | 2025 | Oxlumo |
| Seagen INC. | $15.33 | 2023 | Adcetris |
| Helsinn Therapeutics (U.S.), INC. | $14.80 | 2024 | Akynzeo |
| Ambu INC. | $8.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orlan Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.